Clinical Trial Updates: Schizophrenia Phase 3 Progress, ALS Study Launch & 2026 Human Trial Momentum
Clinical research continues to advance through pivotal psychiatry studies, neurodegenerative disease programs, and emerging therapeutic platforms preparing for first-in-human development. Recent developments include the first patient screened in a Phase 3 schizophrenia trial, a new ALS clinical study launched with a major academic center, and a biotech company advancing toward planned 2026 human trials.
Recent coverage featured by Clinical Trial Vanguard highlights how innovation across neuroscience and advanced therapeutics is progressing through the clinical pipeline.
Minerva Screens First Patient in Phase 3 Schizophrenia Trial
Minerva Neurosciences has screened the first participant in its global confirmatory Phase 3 trial evaluating roluperidone for the treatment of negative symptoms of schizophrenia. The study is expected to enroll approximately 380 patients across around 40 sites in the United States and Europe, with topline efficacy data anticipated in the second half of 2027.
Negative symptoms such as low motivation, social withdrawal, and reduced emotional expression remain a major unmet need in schizophrenia care, making late-stage development particularly significant.
Learn more in Minerva Screens First Patient in Phase 3 Schizophrenia Trial.
Trethera and MGH Launch Clinical Trial for TRE-515 in ALS
Progress in neurodegenerative disease research is also accelerating. Trethera and Massachusetts General Hospital have launched a clinical trial evaluating TRE-515 in amyotrophic lateral sclerosis (ALS). Early-stage ALS studies are especially important because they explore novel mechanisms that may slow progression or improve neuronal resilience.
The collaboration with a leading academic medical center reflects continued momentum in translational neuroscience research.
Further details are available in Trethera & MGH Launch Clinical Trial for TRE-515 in ALS.
Ernexa Therapeutics Advances Toward 2026 Human Trials
Emerging biotech platforms are also progressing toward clinical entry. Ernexa Therapeutics has reported advancement toward planned 2026 human trials, signaling movement from preclinical development into regulated clinical evaluation.
Transitions into first-in-human studies often represent a major milestone for innovative therapeutic technologies, particularly where new modalities or platform approaches are involved.
Read more in Ernexa Therapeutics Advances Toward 2026 Human Trials.
Key Trends Across Current Clinical Research
These developments highlight several broader themes shaping the trial ecosystem:
- Continued advancement of late-stage CNS and psychiatry programs
- Growing investment in ALS and neurodegenerative research
- More biotech platforms reaching first-in-human readiness
Tracking these milestones helps clinicians, sponsors, and researchers understand how neuroscience innovation continues moving from discovery to clinical impact.
